Navigation Links
New angioplasty procedure improves blood flow in blocked arteries to extremities

Patients with blocked arteries to their extremities, known as peripheral artery disease (PAD) or critical limb ischemia (CLI), may now find relief from lower leg pain and wounds caused by impaired leg artery circulation with the previously unproven therapy, percutaneous transluminal angioplasty (PTA). The XCELL trial results now available in Catheterization and Cardiovascular Interventions, a journal published by Wiley on behalf of the Society for Cardiovascular Angiography and Interventions (SCAI), reports that infrapopliteal nitinol stenting to treat CLI is safe and effective in improving wound healing, providing pain relief, and promoting amputation-free survival.

PAD is a disorder in which narrowed blood vessels restrict blood flow in the limbs. CLI affects close to 30 million people in Europe and North America, with most experiencing pain and ulcers with or without gangrene in the legs. Experts agree that current treatment options should aim to relieve pain, heal ulcers, prevent limb loss, improve quality of life and prolong survival. Previous research, however, show amputation rates are as high 40% in CLI patients in the first year following their diagnosis, with mortality rates approaching 20%. Moreover, prior studies estimate that 160,000 amputations due to PAD are performed each year in the U.S., of which a 25% reduction could save $29 billion in health care costs according to the Sage Group.

"With the obesity epidemic, we expect the incidence of diabetes to rise as well, and as these patients age this could sharply increase rates of CLI," explains Dr. Krishna J. Rocha-Singh, MD, FSCAI with Prairie Education & Research Cooperative in Springfield, Ill. "It is essential that we identify less invasive treatment strategies that are safe and effective in improving vascular disease."

One promising procedure for improving CLI outcomes is PTA with stenting of the infrapopliteal arteries. The multi-center trial of the "XpertTM Nitinol Stenting For Critically IschEmic Lower Limbs" (XCELL) evaluates the safety and effectiveness of this device in patients with CLI. The Xpert stent is manufactured by Abbott, a global health care company. The device was evaluated in 120 CLI patients with infrapopliteal lesions of 4-15 cm in length. A total of 140 limbs and 212 implanted devices were included in the study, with 12-month amputation-free survival (AFS), limb salvage, wound healing and pain relief determining the success of the procedure.

Results reveal that 12-month AFS was 78%. Further analysis confirmed that according to baseline Rutherford classes 4, 5, and 6, the 12-month AFS rates were 100%, 77%, 55%, respectively; freedom from major amputation were 100%, 91% and 70%, respectively. The investigators also determined that the 12-month freedom from major amputation rate and clinically driven target lesion revascularization were 90% and 70%, respectively. Six-month and 12-month wound-healing rates were 49% and 54%, respectively. Moreover, Rutherford class 4 patients had significant pain relief through 12 months.

"Our XCELL trial findings confirm that infrapopliteal nitinol stenting is safe and effective in treating CLI patients," concludes Dr. Rocha-Singh. "While there were a few major adverse events, such as death, heart attack, or major amputation that occurred in the first 30 days, at the first year post-procedure, limb preservation, wound healing and pain relief rates were excellent." The authors also point out that the 12-month wound healing with nitinol stenting was similar to the more invasive open surgery.

Contact: Dawn Peters

Related medicine news :

1. Are Post-Angioplasty Stress Tests Unnecessary?
2. Drug May Prevent Pancreatitis After Digestive Procedure
3. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
4. Procedure Might Ease Pain of Female Genital Mutilation
5. Study finds Massachusetts health reform leads to increased inpatient surgical procedures
6. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
7. EVINCI results could lead to 75 percent reduction of invasive procedures for patients with suspected CAD
8. PMIC Announces Release of New CDT 2013 Dental Procedure Coding System
9. Clinical insight improves treatment with new lung cancer drug
10. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the many ... Medical Group . These fields, as well as travel nursing, ranked at ... through the company’s website, , The leading healthcare staffing agency released ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
Breaking Medicine Technology: